Insider Buying: Opko Health Inc. (NASDAQ:OPK) CEO Buys 100,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $1.57 per share, with a total value of $157,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $4,818,253.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, February 11th, Phillip Md Et Al Frost purchased 14,239 shares of Opko Health stock. The stock was bought at an average cost of $1.59 per share, with a total value of $22,640.01.
  • On Thursday, February 6th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.58 per share, with a total value of $79,000.00.
  • On Thursday, January 30th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.42 per share, with a total value of $142,000.00.
  • On Thursday, January 23rd, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.63 per share, with a total value of $81,500.00.
  • On Friday, January 17th, Phillip Md Et Al Frost purchased 22,262 shares of Opko Health stock. The stock was bought at an average cost of $1.56 per share, with a total value of $34,728.72.
  • On Monday, January 13th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.44 per share, with a total value of $72,000.00.
  • On Friday, January 10th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.48 per share, with a total value of $74,000.00.
  • On Wednesday, January 8th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.47 per share, with a total value of $73,500.00.
  • On Monday, December 30th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.47 per share, with a total value of $147,000.00.
  • On Friday, December 27th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.49 per share, with a total value of $149,000.00.

Shares of OPK stock opened at $1.57 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.08 and a debt-to-equity ratio of 0.14. The stock has a 50 day simple moving average of $1.53 and a 200-day simple moving average of $1.73. Opko Health Inc. has a 1-year low of $1.33 and a 1-year high of $2.88.

Several hedge funds have recently made changes to their positions in the company. Alpha Cubed Investments LLC acquired a new position in Opko Health in the 3rd quarter valued at $25,000. Great West Life Assurance Co. Can acquired a new position in Opko Health in the 4th quarter valued at $35,000. Sowell Financial Services LLC acquired a new position in Opko Health in the 4th quarter valued at $59,000. Alpine Global Management LLC acquired a new position in Opko Health in the 4th quarter valued at $61,000. Finally, Hollencrest Capital Management acquired a new position in Opko Health in the 4th quarter valued at $65,000. 21.75% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on OPK shares. BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies started coverage on Opko Health in a research note on Monday, November 25th. They set an “overweight” rating and a $2.50 target price for the company. ValuEngine raised Opko Health from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Finally, Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $2.83.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: What is a Swap?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.